Actively Recruiting
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
Led by University of Illinois at Chicago · Updated on 2026-04-06
400
Participants Needed
1
Research Sites
146 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.
CONDITIONS
Official Title
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 50-80 years of age, inclusive, at the time of signing the Informed Consent Form (ICF).
- Participants must be eligible for low-dose CT screening as defined by the USPSTF.
- USPSTF-eligible patients at UI Health and Mile Square FQHC, including primary care and substance use disorder clinics.
- Adults who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
- Able to provide written informed consent and HIPAA authorization through an approved UIC IRB informed consent form.
- Women of childbearing potential must not be pregnant or breastfeeding and require a negative pregnancy test.
- Ability to understand and comply with study procedures for the entire study duration.
You will not qualify if you...
- Adults who have more than 20 pack-years history but quit smoking 15 or more years prior to informed consent.
- Currently undergoing or referred for diagnostic evaluation due to clinical suspicion of cancer.
- Personal history of invasive solid tumor or hematologic malignancy diagnosed within 5 years prior to enrollment or diagnosed earlier but never treated (except non-metastatic basal or squamous cell carcinoma of the skin).
- Definitive treatment for invasive solid tumor or hematologic malignancy within 5 years prior to enrollment (adjuvant hormone therapy is allowed).
- Unable to comply with protocol procedures.
- Not currently registered patients at UI Health.
- Current pregnancy by self-report.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
A
Ameen Salahudeen, MD, PhD
CONTACT
E
Erica Seltzer, DrPh, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here